2014 European Renal Association-European Dialysis and Transplant Association Congress

2014 European Renal Association-European Dialysis and Transplant Association Congress

Cinacalcet beats parathyroidectomy for improving survival of patients on chronic hemodialysis. The use of a vitamin D receptor activator (VDRA) along with cinacalcet produced additional survival benefit, researchers reported at the European Renal Association—European Dialysis and Transplant Association conference in Amsterdam in June.

A novel compound in development, emapticap pegol (emapticap; NOX-E36, Noxxon Pharma), a drug with anti-inflammatory properties, may be the first disease-modifying drug for the nephropathy in type 2 diabetes mellitus (T2DM). In a presentation at the European Renal Association—European Dialysis and Transplant Association conference in Amsterdam in June, researchers presented evidence that emapticap had positive effects on the kidney that persisted for several weeks after the drug was stopped.

Better dental hygiene and oral health can lead to better overall outcomes for patients with end stage renal disease (ESRD). Researchers saw the effect regardless of the age at which patients initiated oral hygiene practices.

Poor oral health is a risk factor for cardiovascular and all-cause death among patients with chronic kidney disease (CKD). Compared to the general population, dialysis patients have more severe oral disease, and their uptake of dental health services is very low. But questions remain whether improving oral health would result in better outcomes.